Open AccessAssociation Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations
Author(s) -
Jonathan D Cogen,
Anna Faino,
Frankline Onchiri,
Lucas R. Hoffman,
Matthew P. Kronman,
David P. Nichols,
Margaret Rosenfeld,
Ronald L. Gibson
Publication year - 2021
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciab525
Subject(s) - medicine , cystic fibrosis , antibiotics , odds ratio , hazard ratio , pseudomonas aeruginosa , confidence interval , microbiology and biotechnology , genetics , bacteria , biology
Pulmonary exacerbations (PEx) in people with cystic fibrosis (PwCF) are associated with significant morbidity. While standard PEx treatment for PwCF with Pseudomonas aeruginosa infection includes two IV antipseudomonal antibiotics, little evidence exists to recommend this approach. This study aimed to compare clinical outcomes of single versus double antipseudomonal antibiotic use for PEx treatment.